Advice
Following a full submission
methoxy polyethylene glycol-epoetin beta (Mircera) is accepted for use within NHS Scotland for treatment of anaemia associated with chronic kidney disease.
Clinical studies have demonstrated the efficacy of methoxy polyethylene glycol-epoetin beta in correcting and maintaining haemoglobin levels for up to a year in dialysis patients, when administered by either the subcutaneous or intravenous route. Non-inferiority to other erythropoiesis stimulating agents, with respect to achieving and maintaining haemoglobin levels, was demonstrated.
Download detailed advice109KB (PDF)
Medicine details
- Medicine name:
- Methoxy polyethylene glycol-epoetin beta
- SMC ID:
- 455/08
- Indication:
- Treatment of anaemia associated with chronic kidney disease.
- Pharmaceutical company
- Roche
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 April 2008